Expanded Access to Ensartinib for Participants With ALK+ NSCLC
Conditions: Non-Small Cell Lung Cancer; ALK Gene Rearrangement Positive Intervention: Drug: Ensartinib Sponsor: Xcovery Holding Company, LLC Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials